The nonstructural protein 5B (NS5B) of hepatitis C virus (HCV) is the viral RNA-dependent RNA polymerase (RdRp), which is the essential catalytic enzyme for the viral replication and is an appealing target for the development of new therapeutic agents against HCV infection. A small amount of serum from a single patient with hepatitis C was used to get the genome of a Korean HCV isolate. Sequence analysis of NS5B 1701 nucleotides showed the genotype of a Korean isolate to be subtype 1b. The soluble recombinant HCV NS5B polymerase lacking the C-terminal 24 amino acids was expressed and purified to homogeneity. With the highly purified NS5B protein, we established in vitro systems for RdRp activity to identify potential polymerase inhibitors. The rhodanine family compounds were found to be potent and specific inhibitors of NS5B from high throughput screening (HTS) assay utilizing the scintillation proximity assay (SPA) system. The binding mode of an inhibitor was analyzed by measuring various kinetic parameters. Lineweaver-Burk plots of the inhibitor suggested it binds not to the active site of NS5B polymerase, but to an allosteric site of the enzyme. The activity of NS5B in in vitro polymerase reactions with homopolymeric RNA requires interaction with multiple substrates that include a template/primer and ribonucleotide triphosphate. Steady-state kinetic parameter, such as Km, was determined for the ribonucleotide triphosphate. One of compounds found interacts directly with the viral polymerase and inhibits RNA synthesis in a manner noncompetitively with respect to UTP. Furthermore, we also investigated the ability of the compound to inhibit NS5B-directed viral RNA replication using the Huh7 cell-based HCV replicon system. The investigation is potentially very useful for the utility of such compounds as anti-hepatitic agents.
Introduction
HCV infection is the leading cause of sporadic, posttransfusion, non-A non-B hepatitis. 1, 2 One hundred seventy million people worldwide are thought to be infected with hepatitis C virus of which an estimated 4 million reside in the United States. 3, 4 Approximately 80% of infected individuals progress to chronic infection. Long term chronic HCV infection can lead to liver cirrhosis and to hepatocellular carcinoma. Currently, the recommended therapy is treatment with a combination of interferon alpha2b and ribavirin, which results in a sustained viral response (SVR) in 40% of patients. Investigational therapies using a combination of pegylated interferon and ribavirin have lead to a SVR in 54% of patients, but the response rate (42%) of patients harboring HCV genotype 1 is lower. [5] [6] [7] Consequently, additional therapies for HCV infection are needed. HCV is a positive-strand RNA virus belonging to the family Flaviviridae. 8 This virus family also contains about 40 flaviviruses that are associated with human diseases, including the dengue fever viruses, yellow fever viruses and Japanese encephalititis virus. Like other RNA viruses, a virally encoded replication enzyme, RNA-dependent RNA polymerase (RdRp), plays a central role in viral RNA replication of HCV and other members of the family Flaviviridae. In the case of HCV, the replication protein is termed "NS5B" (nonstructural protein 5B). 2, 9 RdRp proteins are the key components of the viral replicase complexes and therefore serve as attractive targets for antiviral development. 1, 15 We cloned, expressed and purified the soluble recombinant HCV NS5B lacking the C-terminal 24 amino acids from a Korean isolate. We chose to determine the nucleotide sequence of a HCV isolate from a single individual diagnosed with acute hepatitis C. The entire NS5B nucleotide and deduced amino acid sequences of this HCV isolate were compared with the the reported full length genotype 1b isolate. With the highly purified NS5B protein, we established in vitro systems for RdRp activity to identify potential polymerase inhibitors. To improve the chances of developing an effective HCV chemotherapeutic by targeting the HCV RNA-dependent RNA polymerase, it is necessary to gain a better understanding of the catalytic activity of the enzyme. Toward that end, this work has been conducted to investigate the enzymatic activity of the soluble, C-terminally truncated form of HCV NS5B, termed NS5Bt. We also measured inhibitory effects with a 50% inhibitory concentration (IC 50 ) of several known inhibitors, and compared them to the reported values. In this report we describe the expression of the NS5B gene in E. coli, purification of the protein and characterization of the enzymatic activity. In addition kinetic data of an inhibitor indicated that the compound acts as an allosteric inhibitor that block the activity of the polymerase prior to the elongation step.
Materials and Methods
Serum Samples and Preparation of cDNA Clones. Serum samples were collected from a patient diagnosed with acute hepatitis C. HCV RNA was extracted from 100 µL of serum with QIAamp Viral RNA Kit (Qiagen Inc.) in conditions recommended by the manufacturer. The isolated RNA was dissolved in DEPC-treated distilled water and stored in freezer until use. HCV single-stranded cDNA was synthesized from the above RNA with 3' polyA primer and 100 units of reverse transcriptase (SuperscriptII, BRL Life Technologies Inc.). Double-stranded cDNA was prepared from single-stranded cDNA with primer, NS5BF (GGGGC-TAGCTCAATGTCCTACTCATGGACAGGC) by using Advantage cDNA PCR Kit (Clontech Inc.) in conditions recommended by the manufacturers.
Cloning, Expression, and Purification of Recombinant HCV NS5B from E. coli. Standard recombinant DNA techniques were used to generate all the constructs. 10 To construct pET21b-NS5Bt, a PCR product containing the cDNA region encoding amino acid 2420-2987 of the HCV polyprotein (the C-terminal 24 amino acids deleted NS5B protein) was cloned between the NheI and XhoI sites of pET21b (Novagen). The sequences of the primers, NS5BF-NheI and NS5BtC-XhoI, are as follows: NS5BF-NheI (GGGGCTAGCTCAATGTCCTA CTCATG-GACAGGC) NS5BtC-XhoI (CCCCCTCGAGCGGGCACGAGACAG-GCTGTGA) pT7-IRES-3'X is a derivative of pcDNA3 (Invitrogen). Template cDNA was synthesized similarly from the isolated HCV RNA with 3'X58R (5'-GGGTCTAGATCATGCGG-CTCACGGACCTTTCACAGCTAG-3') primer. PCR amplifications were performed from the above cDNA template using primer pairs of 5'-GGGTCTAGATCATGCGGCT-CACGGACCTTTCACAGCTAG-3'/5'-TTGAGCCACTT-GACCTACCTCAGATCATTG-3', and consecutively from first PCR product using 5'-CTCTCCAGGTGAGATCAAT-AGGGTGGCTTC-3'/5'-GGGTCTAGACATGATCTGCA-GAGAGGCCAGTATCAGCACTCTCTGCAGTCATGCG GCTCA CGGACCTTTCACAGCTA-3' primers. Second PCR product was digested with HindIII and XbaI, cloned into the corresponding site in pcDNA3 plasmid, and named pT7-IRES-3'X.
C-terminal 24 amino acids deleted NS5B protein (NS5Bt) was expressed in E. coli BL21(DE3) (Novagen) by the following procedures. E. coli BL21(DE3) transformed with pET21b-NS5Bt was grown in Luria-Bertini medium containing 100 µg of ampicillin per ml to an optical density at 600 nm (OD600) of 0.6 at 37 In vitro RdRp Assay. Gel-based RdRp assays were done essentially as described previously 2 with some modifications. Gel-based RdRp assays were conducted by using a 404 base RNA representing the 3'-end of the positive strand from the HCV RNA (3'-X RNA) as a template. In brief, purified were prepared in 100% dimethyl sulfoxide (DMSO), and treated with final concentration of 5% DMSO. After the reaction mixtures were incubated for 2 h at 30 o C, they were stopped by adding proteinase K. RNA products were extracted with Phenol/Chloroform, precipitated with ethanol, and analyzed by 8% polyacrylamide gel electrophoresis (PAGE) under denaturing condition with 8 M urea.
For filter binding RdRp assays, 1 µg of poly(rA), 2.5 µg of oligo(U) 16 and 1 µCi of [5, H]Uridine 5'-triphosphate, ammonium salt (50 Ci/mmol, Amersham Biosciences) were used as described above in place of 3'-X RNA and Uridine 5'-[α-32 P]triphosphate. 5-fold serial dilutions of 10 mM stock test compounds in DMSO were prepared with final concentrations ranging from 100 to 0.03 µM. After the reaction ends, the products were precipitated with 10% trichloroacetic acid (TCA) and applied to a UniFilter-96, GF/B (PerkinElmer) using Cell Harvester (Packard). The 96-well filters were washed 5 times with 10% TCA and 5 times with 95% EtOH, dried, and counted using a Packard TopCount microplate reader.
The HTS RdRp scintillation proximity assay (SPA) was carried out in 96-well plates using 50 nM enzyme, 1 µCi of [5, H]Uridine 5'-triphosphate, 10 µM UTP, 250 nM 5'-biotinylated oligo(U) 16 
Results and Discussion
HCV NS5B genome of a Korean isolate was cloned from cDNA of a single chronic active hepatitis C patient. The nucleotide sequence and deduced amino acid sequence were compared with the reported 1b genotype (Fig. 1) . The percentage identity of the nucleotide and deduced amino acid sequence was 92.7% and 98.7%, respectively, compared with the reported genotype 1b sequence. [12] [13] [14] Since NS5B is considered to have a key function in RNA replication, it is perhaps not surprising that the NS5B protein is highly conserved among the reported 1b isolates.
The NS5B genome of the Korean HCV isolate was amplified with polymerase chain reaction methods. HCV cDNA was prepared from a single patient serum. The PCR product was digested with NheI and XhoI at sites engineered in the primers, and directionally cloned into pET-21b (Novagen) to produce a recombinant protein with a Cterminal 24 amino acid deletion.
E. coli BL21(DE3) containing the pET21b-NS5Bt plasmid produced a protein of approximately 65 kDa under appropriate conditions (Fig. 2) . As the expressed protein at 37 °C with IPTG induction was found in insoluble fractions, we have made efforts to reduce the inclusion body formation. Many culture conditions including reduced concentration of IPTG, longer expression period, lowered expression temperature of to 15 °C and increased aeration of the cultures were applied to produce more soluble NS5B proteins in E. coli culture. When cultures were reached to an OD 600 of 0.6-0.8 at 37 °C, IPTG was added to a final concentration of 0.5 mM. Cultures were continued at 15 °C. Expression of the 65 kDa protein reached a maximum 15 h after the addition of IPTG (Fig. 2) . Cell pellets were harvested and sonicated on ice. The cleared lysate obtained by centrifugation was applied to Ni-NTA resin and heparin resin consecutively. The purified NS5B protein could be used for the RdRp assay without further purification (Fig. 2 ). In case highly purified enzyme is needed, ion exchange column chromatography and desalting process were applied as described in Materials and Methods.
The ability of the purified NS5B enzyme to catalyze a RdRp reaction was determined with a polymerase assay by using several inhibitors and a 404 base RNA template (3'-X RNA), representing the 3'-end of the positive HCV RNA strand. Briefly, the purified protein was incubated with 3'-X RNA in a total volume of 40 µL of RdRp buffer, 10 µCi of Uridine 5'-[α-32 P]triphosphate, 0.5 mM each of the remaining NTP and 10 µM UTP. Serial dilutions of each inhibitor were prepared in 100% DMSO, and treated with a final concentration of 5% DMSO. After incubation for 2 h at 30 o C, the reaction mixtures were analyzed by 8% PAGE under denaturing condition with 8 M urea. Pyrophosphate, the pyrophosphate analogs (phosphonoacetic acid and phosphonoformic acid) and inhibitors of several DNAdependent DNA polymerases (GDP, dGTP and ddCTP) had no significant effects in concentrations up to 100 µM (Fig.   3A) . A moderate inhibition of RdRp activity was obtained with cerulenin, a specific inhibitor of fatty acylation and sterol biosynthesis. It was shown that cerulenin blocks poliovirus replication in infected cells. 16 Also inhibitors of several DNA-dependent RNA polymerases such as mycophenolic acid and gliotoxin show a weak inhibition at high concentrations (Fig. 3B) . However, ddUTP as a general inhibitor of RNA polymerase, shows much stronger inhibition at 100 µM (Fig. 3C) , suggesting that the purified enzyme behaviors like RdRp.
In summary, the properties described here for NS5B of HCV are very similar to those reported for several picornaviral polymerases, [17] [18] [19] and they suggest that the NS5B enzymes are closely related in function and possibly in structure to the picornaviral polymerases.
Since NS5B is the key player in RNA replication, the RdRp assay might be used as a starting point for the development of an antiviral therapy. Therefore, we measured inhibitory effects with a 50% inhibitory concentration (IC 50 ) of two known inhibitors (Fig. 4) . Inhibitors, named Merck I and II, have the reported IC 50 values of 0.7 µM and 0.056 µM, respectively. 20 Our measurements with the purified NS5B protein show an excellent dose-dependency on the compounds. IC 50 values were determined from doseresponse curves (Fig. 4) using 6 concentrations for each compound. Curves were fitted to data points using nonlinear regression analysis and IC 50 values were interpolated from the resulting curves using Microsoft Excel software. We found that the measured IC 50 values were very similar to the reported values (Table 1) .
Recently, a three-dimensional structure of the HCV polymerase was solved in complex with RNA 21 as well as in a complex with nucleoside triphosphates. 22 Three distinct nucleotide-binding sites were observed in the catalytic center of HCV RdRp whose geometry was remarkably similar to that observed in the initiation complex of the RNA phage Φ6 RdRp. 23 An unexpected result of this study was the observation of a GTP-binding site on the enzyme surface at the interface between the finger and thumb domains, 30 Å away from the polymerase catalytic center. 22 This previously unidentified GTP pocket was proposed to be a potential allosteric regulatory site that could modulate alternative interactions between the two domains during the conformational change of the enzyme that is required for efficient initiation. The presence of a unique nucleotide-binding site away from the enzyme catalytic center could potentially provide an attractive target for allosteric inhibitors of the HCV polymerase reaction. Therefore, we established high-throughput screening assays using a SPA bead system with our own RdRp activity conditions. High-throughput screening of the LGLS proprietary compound archive identified a novel rhodanine NS5B inhibitor whose chemical structure is shown in Figure  6 . Compound LB80524 demonstrated inhibition of NS5B polymerization activity with a calculated IC 50 value of 5.0 ìM. Subsequent kinetic experiments demonstrated that the Km for UTP was 4.9 µM (Fig. 5) . Furthermore, mechanistic enzymology studies with compound LB80524 suggest that this inhibitor exhibits a kinetic behavior consistent with a reversible, noncompetitive mechanism of inhibition with respect to UTP. A noncompetitive inhibition of UTP incorporation by the compound LB80524 was displayed as a Lineweaver-Burk plot (Fig. 7) . To determine the inhibitory mode of LB80524 in RNA synthesis catalyzed by NS5B, reactions were run in which the concentrations of UTP and LB80524 were varied, respectively. Double-reciprocal plots of the data as shown in Figure 7 indicated noncompetitive inhibition of activity by LB80524 with varying concentrations of UTP. However, the rhodanine compound was able to inhibit the HCV replication only weakly in HCV replicon cells (EC 50 = 40 µM). The implication associated with activity in the replicon cells is that the inhibitor was not able to access the perinuclear membrane easily, the site of viral RNA synthesis.
In conclusion we isolated a HCV NS5B genome (genotype 1b) from a Korean hepatitis C patient, cloned it, and expressed it in E. coli. With the highly purified NS5B protein, we established in vitro systems for RdRp activity to identify potential polymerase inhibitors. We found a potent inhibitor against HCV RdRp by utilizing the established in vitro systems, and characterized the mode of inhibition by investigating kinetic studies. This assay is a highly reproducible, non-labor intensive, and cost effective assay. In addition this assay is easily adaptable to automation in a high-throughput format. 
